

## Review: Drug Evaluation Methods and Innovations

Sai Prasanna LM\*

Department of Chemical Engineering, Rajiv Gandhi University of Knowledge Technologies, IIIT-Nuzvid, Krishna, 521201, India

### Review Article

Received: 27/08/2016  
Accepted: 28/08/2016  
Published: 31/08/2016

\*Corresponding author: Sai Prasanna LM, Department of Chemical Engineering, Rajiv Gandhi University of Knowledge Technologies, IIIT-Nuzvid, Krishna, 521201, India.

E-mail: [manjuhanuma@gmail.com](mailto:manjuhanuma@gmail.com)

Keywords: Drug, Cancer, Evaluation, Diabetes.

### Abstract

The aim of this review is to provide knowledge on importance of drug evaluation, and different evaluation methods available. Drug evaluation is to distinguish and decide the nature of the rough drug and identifying the way of adulteration. Also present new innovations in treating cancer, diabetes, and other deceases.

## INTRODUCTION

A pharmaceutical drug is a medication used to analyze, cure, treat, or avoid disease. Drug treatment is a vital part of the restorative field and depends on the art of pharmacology for nonstop progression and on drug store for suitable administration [4-5]. Drugs are divided in different ways. One of the key divisions is by level of control, which recognizes doctor prescribed drugs from over-the-counter drugs. Another key refinement is between conventional little atom drugs, typically got from synthetic combination, and biopharmaceuticals, which incorporate recombinant proteins, immunizations, blood items utilized restoratively, quality treatment, monoclonal antibodies and cell treatment [6-10]. Different approaches to arrange solutions are by method of activity, course of organization, natural framework influenced, or restorative impacts. An elaborate and generally utilized arrangement framework is the Anatomical Therapeutic Chemical Classification System [11].

Drug design and advancement are perplexing and costly tries attempted by pharmaceutical organizations, scholarly researchers, and governments [12-16]. Governments by and large manage what drugs can be advertised, how medications are showcased, and in a few locales, drug estimating. Debates have emerged over medication valuing and transfer of utilized medications [17]. Drug evaluation is the procedure by which harmfulness, metabolism, assimilation, end, favored course of organization, safe measurement range for a drug or gathering of drugs can be determined by resolved through clinical evaluation in people or veterinary creatures [18-23].

The aim of drug evaluation is to distinguish and decide the nature of the rough drug and identifying the way of adulteration [24,25]. The evaluation of raw drug is crucial in light of the fact that, there might be biochemical varieties in the drug, there might be deterioration because of storage, substitution and debasement might be present as a consequence of carelessness [26-30]. The crude drugs can be distinguished on the premise of their morphological, histological, and synthetic characters.

## Methods of Drug Evaluation

**Morphological and organoleptic evaluation:** It analyses the drug evaluation by shading, scent, taste, size, shape and uncommon elements like surface [31-35].

**Microscopic evaluation:** This technique permits more point by point examination of a medication and their distinguishing proof by their known histological characters [36]. Magnifying lens by the uprightness of its property to

# Research & Reviews: Journal of Pharmaceutical Quality Assurance

amplify, grants minute segments under study to develop so that, leaf constants, stomata file, palisade proportion can be resolved [37-42].

**Physical evaluation:** These are once in a while consistent for crude drugs, however may help in evaluation with reference to dampness content, particular gravity, thickness, optic pivot, refractive list, dissolving point, thickness, solvency and so forth [43,44].

**Chemical evaluation:** It deals with various chemical test and measures. The disconnection, cleansing and distinguishing proof of dynamic constituents are the strategies for evaluation [45-47]. Quantitative synthetic test, for example, corrosive quality, saponification esteem and so on are additionally secured under these strategies [48-51].

**Biological evaluation:** Whenever physical or chemical techniques for evaluation are not giving satisfactory result in drugs then the drugs are assessed by natural strategies for evaluation [52-56]. These strategies are performed on living creatures, disengaging living organ and tissue, creature arrangement and small scale living being [57-61]. The natural techniques for evaluation is performed on living being are called bioassay or organic test [62-65].

## Biological methods of evaluation

1. Anti-inflammatory action of medications
2. Anti-pyretic movement of medications
3. Hostile to diabetic action of medications
4. Pain relieving movement of medications
5. Anti-ulcer movement of medications
6. Anthelmintic movement of medication
7. Cardiovascular action of medication
8. Microbiological techniques

## Medical Innovations

**Treatment of cancer:** Since ordinary chemo tranquilizes unpredictably slaughter all quickly separating cells to stop the development of tumor, these specific nanoparticles could diminish reactions by lessening drug collection in typical cells [66]. The discovery that nanoparticles can be particular to specific cells construct just with respect to their physical and compound properties has significant ramifications for nanoparticle-based treatments since cell sort specificity of medication bearers could change understanding results in the center [67-70]. In the meantime, a more profound comprehension of nanoparticle associations in the body opens the way to foresee tolerant reactions to existing liposome and nanoparticle treatments, and offers the possibility to make future medication transporters altered by hereditary profiles.

The researchers tried several polymers to make the astounding disclosure that cells could react contrastingly to the same drug bearer, even when those carcinogenic and ordinary cells originated from the lungs of the same patient [71-76]. Amazingly, the malignancy specific nanoparticles stayed within tumors in mice for over one week, while nonselective control nanoparticles were cleared inside a couple of hours. This meant enhanced siRNA-interceded malignancy cell demise and noteworthy concealment of tumor development.

**Ovarian cancer:** Another class of drugs could be a critical stride forward in the treatment of ovarian tumor, a standout amongst the most deadly types of the sickness [77]. The medications, known as PARP inhibitors, are thought to help the body moderate the malady's movement by keeping growth cells from repairing themselves after chemotherapy treatment, accordingly contracting tumors and postponing backslides [78-81]. The medications don't work in everybody, and are thought to have the best impact in ladies with transformations of the BRCA qualities, who speak to around 15% of ovarian-tumor patients. However, late research, as yet continuous, shows that the medications may profit an extra 35% of patients with various hereditary profiles [82,83].

**Nanofishes:** These new nanobots are 100 times littler than a grain of sand and comprise of small gold and nickel sections that are associated with silver pivots [84-87]. An outer magnet is utilized to control the nickel and make a waving movement to move the bot forward. The velocity and heading of the little swimmer is dictated by the introduction and quality of the attractive field. These will have the capacity to deliver drugs like pain drug to the particular range of the body that need it [88].

**Treating diabetes:** The U.S. Nourishment and Drug Administration endorsed Adlyxin (lixisenatide), and

# Research & Reviews: Journal of Pharmaceutical Quality Assurance

once-every day infusion to enhance glycaemic control (glucose levels), alongside eating routine and activity, in grown-ups with sort 2 diabetes [89-93]. Type 2 diabetes influences more than 29 million individuals and records for more than 90% of diabetes cases analyzed in the United States. After some time, high glucose levels can expand the danger for genuine entanglements, including coronary illness, visual impairment and nerve and kidney harm [94,95]. Utilization of Adlyxin did not build the danger of cardiovascular unfavorable occasions in these patients.

**Treating asthma:** Asthma is a constant sickness that causes irritation in the aviation routes of the lungs. Amid an asthma assault, aviation routes get to be slender making it difficult to relax [96]. Extreme asthma assaults can prompt asthma-related hospitalizations in light of the fact that these assaults can be not kidding and even life-undermining. As per the Centre's for Disease Control and Prevention, starting 2013, more than 22 million individuals in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year. Compared with fake treatment, patients with serious asthma accepting Cinqair had less asthma assaults, and a more drawn out time to the main assault [97]. What's more, treatment with Cinqair brought about a huge change in lung capacity, as measured by the volume of air breathed out by patients in one second.

**Controlling sugar levels:** Another new advancement is that patients inclined to amazing variances in sugar levels no more need to experience the nerve racking knowledge of punching themselves to get drug [98]. New medications, for example, Victoza, a day by day single measurement medication, and Trulicity, a week after week medication (that is non-insulin) has been presented in India early this year [99].

Medications, for example, ACE-I, ARBs, Hydralazine/Nitrates and beta-blockers too are demonstrating promising with regards to heart disappointment [100]. Heart transplantation is today turning into the treatment of decision for the treatment of end-stage heart disappointment and has been appeared to expand life-range while additionally enhancing exercise limit and personal satisfaction.

## CONCLUSION

The evaluation of drug is crucial before its production in order to know the chemical, toxicological, physical characteristics. So, that appropriate actions can be done in accordance. Among all biological evaluation give appropriate results as they are tested in living organisms i.e., bacteria, rats etc. PARP inhibitors are thought to help the body moderate the malady's movement by keeping growth cells from repairing themselves after chemotherapy treatment, accordingly contracting tumors and postponing backslides. Nanobots have the capacity to deliver drugs like pain drug to the particular range of the body that need it.

## REFERENCES

1. Abdel-Hamid NM, et al. Golden Forms of Nano-Sized Anticancer Drugs. 2012;1:1.
2. Thanou M and Duncan R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs. 2003;4:701-709.
3. Vasir JKR, and Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Current Nanosci. 2005;1:47-64.
4. Zahr AS, et al. Encapsulation of drug nanoparticles in self-assembled macromolecular nanoshells. Langmuir. 2005;21:403-410.
5. Dorsett Y and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov. 2004;3:318-329.
6. Ben Othman A, et al. Comparison of Acinetobacter baumannii multidrug resistant Isolates obtained from French and Tunisian hospitals. J Bacteriol Parasitol. 2011;2:106.
7. Wee T and Jenssen H. Influenza Drugs – Current Standards and Novel Alternatives. J Antivir Antiretrovir. 2009;1:1-10.
8. Uchiumi F, et al. Development of Novel Anti-aging Drugs. Pharm Anal Acta. 2011;2:106e.
9. Patil A, et al. Encapsulation of Water Insoluble Drugs in Mesoporous Silica Nanoparticles using Supercritical Carbon Dioxide. J Nanomedic Nanotechnol. 2011;2:111.
10. Caraglia M, et al. Nanotechnologies: New Opportunities for Old Drugs. The Case of Aminobisphosphonates. J Nanomedic Biotherapeu Discover. 2011;1:103e.
11. Prakash N, et al. Molecular Docking Studies of Antimalarial Drugs for Malaria. J Comput Sci Syst Biol. 2010;3:70-73.
12. Arroyo A, et al. Times of Detection of Drugs of Abuse in Saliva: Study of Arrested Population. J Forensic Res. 2011;2:114.
13. Grane OM, et al. Alarming Trends in a Novel Class of Designer Drugs. J Clinic Toxicol. 2011;1:108.

# Research & Reviews: Journal of Pharmaceutical Quality Assurance

14. Chen QM, et al. Study on Slice-based Biosensor for Electrophysiological Propagation Measurement in Drugs Screening. *J Biochip Tissue chip*. 2011;S1:4.
15. Hashemi M, et al. Mechanistical Approach Through Discovery of New Generations of Anti Inflammatory Drugs. *J Proteomics Bioinform*. 2011;4:284-288.
16. Hiwasa T, et al. Functional Similarity of Anticancer Drugs by MTT Bioassay. *J Cancer Sci Ther*. 2011;3:250-255.
17. Haque SS. Antioxidant Status of Formulated Drugs Against Typhoid. *Biochem & Anal Biochem*. 2011;1:102.
18. Tzakos AG. Intrinsic Protein Disorder as a Drug Target in Oncology: Designing Drugs Targeting Plasticity. *Biochem Pharmacol*. 2011;1:e107.
19. Modak AS. Phenotype Breath Tests as Companion Diagnostic Tests (CDx) in Clinical Trials of Drugs. *J Pharmacogenomics Pharmacoproteomics*. 2012;3:e106.
20. Johanning GL. Stapled Peptides as Anti-Apoptotic Drugs. *Chemotherapy*. 2012;1:e109.
21. Putz G. Dosing of Chemotherapeutic Drugs – Time to Leave the Stone Age. *Chemotherapy*. 2012;1:e108.
22. Ibrahim HR. Anti-Infective Drugs: Why Should We Pay Attention? *J Develop Drugs*. 2012;1:e112.
23. Yano S, Kobayashi K, Ikeda T (2012) Adjunctive Corticosteroid to Counteract Adverse Drug Reactions from First-Line Antituberculous Drugs. *Mycobac Dis* 2:113.
24. Bains S, Shah AA (2012) Sexual Side Effects of Antipsychotic Drugs. *Adv Pharmacopidem Drug Safety* 1:109.
25. Sohn HS, et al. Out-of-Pocket (OOP) Expenditure for Prescription Drugs among South Korean Outpatients under the National Health Insurance System: Focus on Chronic Diseases Including Diabetes. *J Diabetes Metab*. 2012;3:197.
26. Devieux J, et al. Impulsivity and HIV risk among adjudicated alcohol- and other drug-abusing adolescent offenders. *AIDS Educ Prev*. 2002;14:24-35.
27. Neaigus A. The network approach and interventions to prevent HIV among injection drug users. *Public Health Rep*. 1998;113:140-150.
28. Dent CW, et al. Project Toward No Drug Abuse: generalizability to a general high school sample. *Prev Med*. 2001;32:514-520.
29. Abrantes AM, et al. Substance use disorder characteristics and externalizing problems among inpatient adolescent smokers. *J Psychoactive Drugs*. 2005;37:391-399.
30. Gosin M, et al. Keep in it R.E.A.L.: A drug resistance curriculum tailored to the strengths and needs of pre-adolescents of the Southwest. *J Drug Educ*. 2003;33:119-142.
31. Milazzo V, et al. Drugs and Orthostatic Hypotension: Evidence from Literature. *J Hypertens*. 2012;1:104.
32. Rahman M, et al. Genetic Characterization of Hepatitis C Viruses in HIV Positive People who Inject Drugs, Dhaka, Bangladesh. *J AIDS Clinic Res*. 2012;3:165.
33. Sulejmani Z, et al. Abuse of Pharmaceutical Drugs-antibiotics in Dairy Cattle in Kosovo and Detection of their Residues in Milk. *J Ecosyst Ecogr*. 2012;2:114.
34. Banaei-Boroujeni S, et al. Abstaining Opioid Drugs as a Possible Risk Factor for Graves' Disease. *J Addict Res Ther*. 2012;3:131.
35. Mascellino MT, et al. Candidaemia in Immune-Compromised Hosts: Incidence and Drugs Susceptibility. *J Clin Exp Pathol*. 2012;2:131.
36. Preissner S, et al. Drug Interactions Involving the Cytochrome P450 Enzymes: Analysis of Common Combinations of Antibiotics and Pain Relieving Drugs. *J Drug Metab Toxicol*. 2012;3:131.
37. Lepesheva GI, et al. CYP51: A major drug target in the cytochrome P450 superfamily. *Lipids*. 2008;43:1117-1125.
38. Gardiner SJ and Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. *Pharmacol Rev*. 2006;58:521-590.
39. Radhakrishnan ML and Tidor B. Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. *J Chem Inf Model*. 2008;48:1055-1073.
40. Casacó A, et al. Anti- Epidermal Growth Factor/Epidermal Growth Factor Receptor Therapeutic Anticancer Drugs and the Wound Healing Process. *J Cancer Sci Ther*. 2012;4:324-329.
41. Nazer M, et al. Evaluation of Type of Adolescents' Beliefs about Harmfulness Addictive Drugs and the Role of Education in Changing their Opinion (Health Belief Model). *J Psychol Psychother*. 2013;3:107.
42. McCabe SE, et al. Subtypes of nonmedical prescription drug misuse. *Drug Alcohol Depend*. 2009;102:63-70.
43. Sung JH and Park JS. The effect of drug abuse prevention program for elementary school students. *Taehan Kanho Hakhoe Chi*. 2004;34:421-429.
44. Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. *Nat Rev Drug Discov*. 2007;6:967-974.

# Research & Reviews: Journal of Pharmaceutical Quality Assurance

45. Amaro RE, et al. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. *J Am Chem Soc.* 2007;129:7764-7765.
46. Russell RJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. *Nature.* 2006;443:45-49.
47. Mitrasinovic PM. Advances in the structure-based design of the influenza A neuraminidase inhibitors. *Curr Drug Targets.* 2010;11:315-326.
48. Garman RM. This is your Brain on Drugs: SUD, Cognitive Impairment, and Mental Health Disorders. *J Addict Res Ther.* 2013;4:141.
49. Abdallah NA, et al. HPLC and Densitometric TLC Methods for Simultaneous Determination of Pazufloxacin with Some Coadministered Drugs in Human Plasma. *J Chromat Separation Techniq.* 2012;3:161
50. Li Q, et al. Determination of pazufloxacin mesylate in human plasma and urine by high performance liquid chromatography. *Asian J Drug Met Pharmacokinet.* 2004;4:289-293.
51. Sheng L, et al. Influence of cefoperazone and azithromycin on the pharmacokinetics of pazufloxacin in rats. *Eur J Drug Metab Pharmacokinet.* 2007;32:219-223.
52. López-Muñoz F, et al. A Bibliometric Study of Scientific Research on Second-Generation Antipsychotic Drugs in Hong Kong. *Clin Exp Pharmacol.* 2013;3:124.
53. López-Muñoz F and Álamo C. Neurobiological background for the development of new drugs in schizophrenia. *Clin Neuropharmacol.* 2011;34:111-126.
54. Mortimer AM, et al. Primary care use of antipsychotic drugs: an audit and intervention study. *Ann Gen Psychiatry.* 2005;4:18.
55. Stocco B, et al. The Effect of Different Contraceptive Drugs on the Lipid Profile of Brazilian Women. *Pharmaceut Anal Acta.* 2013;4:208.
56. Mishra RP and Mishra S. In Vitro Assessment of Genotoxicity of Some Ayurvedic Drugs in Human Lymphocytes by Using Single Cell Gel Electrophoresis. *J Drug Metab Toxicol.* 2013;4:139.
57. Sathya TN, et al. Genotoxicity evaluation of certain Bhasmas using micronucleus and comet assays. *The Internet J of Alternative Medicine.* 2009;7:1.
58. James Kirkpatrick C, et al. Non-Equivalence of Antibiotic Generic Drugs and Risk for Intensive Care Patients. *Pharmaceut Reg Affairs.* 2013;2:109.
59. Bharadwaj S, et al. An Open Comparative Randomized Clinical Study of Plant Based Drugs *Embelia Robusta* Roxb and *Mallotus Philippinensis* Muell on Intestinal Parasites. *J Gastroint Dig Syst.* 2013;3:122.
60. Khan AU, et al. Effect of Reconstitution Solvents and Containers on Kinetics and Safety of Cephadrine Neutralized with L-Arginine. *J Drug Metab Toxicol.* 2013;4:150.
61. Presoti AR, et al. Prescription of Drugs to be Administered through Feeding Tubes in a Brazilian Hospital: Profile and Qualification. *J Gen Pract.* 2013;1:112.
62. Ajanal M and Prasad BS. Generalized Skin Rashe After Oral Administration of Ayurvedic Drugs: An Unintended Drug Reaction. *J Homeop Ayurv Med.* 2013;2:128.
63. Jampilek J. Transdermal Application of Drugs and Techniques Affecting Skin Barrier. *J Bioequiv Availab.* 2013;5:233-235.
64. El-Nabarawi MA, et al. Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. *Int J Pharm.* 2013;443:307-317.
65. Benson HA. Transdermal drug delivery: penetration enhancement techniques. *Curr Drug Deliv.* 2005;2:23-33.
66. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. *Eur J Pharm Sci.* 2001;14:101-114.
67. Fang JY and Leu YL. Prodrug strategy for enhancing drug delivery via skin. *Curr Drug Discov Technol.* 2006;3:211-224.
68. Prow TW, et al. Nanoparticles and microparticles for skin drug delivery. *Adv Drug Deliv Rev.* 2011;63:470-491.
69. Johnson ME, et al. Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery. *J Pharm Sci.* 1996;85:670-679.
70. Mitragotri S, et al. Transdermal drug delivery using low-frequency sonophoresis. *Pharm Res.* 1996;13:411-420.
71. Bariya SH, et al. Microneedles: an emerging transdermal drug delivery system. *J Pharm Pharmacol.* 2012;64: 11-29.
72. Magyar I, et al. The Rational Use of Mucolytic Drugs in Children: Worsening of the Cough as Adverse Drug Reaction after Carbocysteine in Children. *Clin Exp Pharmacol.* 2013;3:140.
73. McCarthy JP, et al. Treatment of Herpes Labialis: Repetition of a Study Comparing Two OTC Drugs and Untreated Controls and Comparing the Outcomes of Each Study. *Dentistry.* 2013;4:185.
74. Alfadl AA, et al. The Impact of Demographic Characteristics on Vulnerability of Consumers to Counterfeit

# Research & Reviews: Journal of Pharmaceutical Quality Assurance

- Drugs in a Developing Country. *J Socialomics*. 2013;2:102.
75. Bird RC. Counterfeit drugs: A global consumer perspective. *Wake Forest Intellectual Property Law J*. 2008;8:387-406.
  76. Orekhov AN. Anti-atherosclerotic Drugs from Natural Products. *Nat Prod Chem Res*. 2013;1:121
  77. Gareri P, et al. Iatrogenic Delirium in an Elderly Patient: When Drugs are Harmful. *J Gerontol Geriat Res*. 2014;3:140.
  78. Källén B. Maternal Asthma and Use of Antiasthmatic Drugs in Early Pregnancy and Congenital Malformations in the Offspring. *J Pulm Respir Med*. 2014;4:166.
  79. Moriwaki Y. Effects on Uric Acid Metabolism of the Drugs except the Antihyperuricemics. *J Bioequiv Availab*. 2014;6:10-17.
  80. Santos-Oliveira R. Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals: Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs. *J Bioequiv Availab*. 2014;6:23.
  81. Itrat M and Khan JA. Anti-Aging Drugs in Unani Medicine. *J Community Med Health Educ*. 2014;4:275.
  82. Alqahtani JM and Asaad AM. Anti-Tuberculous Drugs and Susceptibility Testing Methods: Current Knowledge and Future Challenges. *J Mycobac Dis*. 2014;4:140.
  83. Abd El-Wahed MG, et al. Outline about Biological and Chemical Coordinations of Some Sulphonyl Drugs. *J Infect Dis Ther*. 2014;2:132.
  84. Palmer KJ and Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. *Drugs*. 1993;46:92-125.
  85. Reven S, et al. Hyperbranched poly(esteramides) as solubility enhancers for poorly water-soluble drug glimepiride. *Int J Pharm*. 2010;396:119-126.
  86. Refat MS and Mohamed SF. Spectroscopic, thermal and antitumor investigations of sulfasalazine drug in situ complexation with alkaline earth metal ions. *Spectrochim Acta A Mol Biomol Spectrosc*. 2011;82:108-117.
  87. Ortega-Albás JJ and Gomis Devesa AJ. Hypnotic-Sedating Drugs in the Treatment of Insomnia: Objective or Subjective Improvement?. *J Sleep Disord Ther*. 2014;3:158.
  88. Ohru H. A New Paradigm for Developing Antiviral Drugs Exemplified by the Development of Supremely High Anti-HIV Active EFdA. *J Antivir Antiretrovir*. 2014;6:32-39.
  89. Moore PW, et al. Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. *J Blood Disord Transfus*. 2014;5:195.
  90. Masson MJ, et al. The role of cytokines in the mechanism of adverse drug reactions. *Handb Exp Pharmacol*. 2010;2:195-231.
  91. Hauben M, et al. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. *Drug Saf*. 2007;30:143-155.
  92. Hauben M. Early postmarketing drug safety surveillance: data mining points to consider. *Ann Pharmacother*. 2004;38:1625-1630.
  93. Hauben M and Reich L. Safety related drug-labelling changes: findings from two data mining algorithms. *Drug Saf*. 2004;27:735-744.
  94. Torfgård KE and Ahlner J. Mechanisms of action of nitrates. *Cardiovasc Drugs Ther*. 1994;8:701-717.
  95. Scarlet C. Anaphylaxis. *J Infu Nurs*. 2006;29:39-44.
  96. Saxena SK, et al. Current Scenario of Antiviral Drugs for Japanese Encephalitis. *J Med Microb Diagn*. 2014;3:133.
  97. Khan S, et al. Multiple Drug Induced Hypersensitivity Syndrome Reactions in a Patient with Drugs that Have Known HLA Associations for Reactions. *Gen Med*. 2014;2:133.
  98. Urso L, et al. Antiepileptic Drugs, Sexual Functions and Serum Hormonal Profile in Males with Epilepsy. *Med Surg Urol*. 2014;3:130.
  99. Assob JCN, et al. Incidence and Risk Factors of Anti-tuberculosis Drugs Induced Hepatotoxicity in HIV/AIDS Patients Attending the Limbe and Buea Regional Hospitals. *J AIDS Clin Res*. 2014;5:288.
  100. Huang HN, et al. Modulation of the immune-related gene responses to protect mice against Japanese encephalitis virus using the antimicrobial peptide, tilapia hepcidin 1-5. *Biomaterials*. 2011;32:6804-6814.